Montreal, November 11, 2015. – The Chairman of the Board, Dr. Léon Gosselin, and the President and CEO of CQDM, Dr. Diane Gosselin, are pleased to announce the appointment of Dr. Uwe Schoenbeck, Chief Scientific Officer, External Research & Development Innovation (ERDI), Pfizer Inc., as member of CQDM’s Board of Directors. Pfizer is a founding partner…
Toronto, October 29, 2015. – BioWin, the Health Cluster of Wallonia, and the Government of Wallonia entered into a collaborative agreement with the Canadian consortium CQDM and launched a new Canada/Wallonia joint funding program. This new international collaborative agreement will help Canadian SMEs and academic researchers work jointly with SMEs from the Walloon region of…
Montreal, October 6th, 2015. – CQDM and AiF Projekt GmbH, the project management agency of BMWi, the German Ministry for Economic Affairs and Energy, are very pleased to announce the launch of a new international funding initiative entitled the Canada/Germany joint program, within CQDM’s Canada/Europe joint funding initiative. This collaboration agreement aims at funding collaborative…
Montreal, July 29th, 2015. – CQDM and CIHR, through its institutes of Cancer Research, Genetics and Infection and Immunity, are pleased to announce $1.5M in funding for two translational projects in personalized medicine, to accelerate drug discovery and drug development. One project will be led by Dr. Henry Krause from the University of Toronto and the other one…
CQDM and MaRS Innovation investing in new Encycle project to determine rules for making peptide drugs orally bioavailable, a biotechnology company founded by Dr. Andrei Yudin of the University of Toronto in partnership with MaRS Innovation, is a Canadian start-up emerging as a market leader in finding orally-bioavailable molecules. Today, the company announced $840,000 in funding from…
Philadelphia, June 16, 2015. – CQDM and Ontario Centres of Excellence(OCE) will fund five highly innovative and unconventional game-changing research and development projects to accelerate drug discovery in the Quebec-Ontario Life Sciences Corridor. Partners are granting $1.5M to Quebec-based and, for the first time, Ontario-based researchers thanks to the partnership with OCE through CQDM’s 2014 Explore…
Vancouver, May 26, 2015. – CQDM, Brain Canada and the Ontario Brain Institute (OBI) award close to $8.5M to six (6) multi-disciplinary and multi-provincial research teams across Canada to address unmet needs in neuroscience within their Focus on Brain strategic initiative. To this amount, $1.5M is added from the various research entities involved as in-kind…
Montreal, April 15th, 2015 – The Chairman of the Board, Dr. Léon Gosselin, and the President and CEO of CQDM, Dr. Diane Gosselin, are pleased to announce the appointment of Dr. Michel Goldman, former Executive Director at the Innovative Medicines Initiative (IMI), as member of CQDM’s Board of Directors. Michel Goldman led the IMI from 2009 to 2014…
CQDM supports precompetitive research whose technological breakthroughs will boost the productivity of biopharmaceutical R&D and provide solutions to the unmet critical needs of the industry. Although CQDM members share costs, risks and research results, the intellectual property resulting from the CQDM-funded research will belong to the researchers and their respective institutions. A non-exclusive license option will…
Montreal, January 19, 2015. – CQDM is very pleased to announce that Janssen Inc. (Janssen) is joining its public-private consortium to support highly innovative, collaborative research in Canada to accelerate drug discovery and development, in order to bring better treatments to patients. The new partnership with Janssen brings to nine (9) the number of pharmaceutical companies around…